A detailed history of Blair William & CO transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Blair William & CO holds 421,470 shares of GILD stock, worth $38 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
421,470
Previous 425,559 0.96%
Holding current value
$38 Million
Previous $29.2 Million 21.0%
% of portfolio
0.11%
Previous 0.09%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$66.59 - $83.99 $272,286 - $343,435
-4,089 Reduced 0.96%
421,470 $35.3 Million
Q2 2024

Aug 12, 2024

BUY
$63.15 - $72.88 $447,228 - $516,136
7,082 Added 1.69%
425,559 $29.2 Million
Q1 2024

May 09, 2024

SELL
$71.58 - $87.29 $3.65 Million - $4.45 Million
-50,963 Reduced 10.86%
418,477 $30.7 Million
Q4 2023

Feb 12, 2024

SELL
$73.27 - $83.09 $158,263 - $179,474
-2,160 Reduced 0.46%
469,440 $38 Million
Q3 2023

Nov 09, 2023

SELL
$73.94 - $80.67 $984,141 - $1.07 Million
-13,310 Reduced 2.74%
471,600 $35.3 Million
Q2 2023

Aug 11, 2023

SELL
$76.01 - $86.7 $218,224 - $248,915
-2,871 Reduced 0.59%
484,910 $37.4 Million
Q1 2023

May 12, 2023

SELL
$77.31 - $88.08 $2.48 Million - $2.83 Million
-32,133 Reduced 6.18%
487,781 $40.5 Million
Q4 2022

Feb 10, 2023

BUY
$62.32 - $89.47 $2.16 Million - $3.1 Million
34,625 Added 7.13%
519,914 $44.6 Million
Q3 2022

Nov 09, 2022

SELL
$59.54 - $68.01 $333,126 - $380,515
-5,595 Reduced 1.14%
485,289 $29.9 Million
Q2 2022

Aug 10, 2022

SELL
$57.72 - $65.01 $1.55 Million - $1.74 Million
-26,806 Reduced 5.18%
490,884 $30.3 Million
Q1 2022

May 13, 2022

SELL
$57.92 - $72.58 $4.13 Million - $5.18 Million
-71,377 Reduced 12.12%
517,690 $30.8 Million
Q4 2021

Feb 14, 2022

BUY
$64.88 - $73.64 $842,401 - $956,141
12,984 Added 2.25%
589,067 $42.8 Million
Q3 2021

Nov 12, 2021

SELL
$67.69 - $73.03 $2.97 Million - $3.2 Million
-43,866 Reduced 7.08%
576,083 $40.2 Million
Q2 2021

Aug 12, 2021

SELL
$63.47 - $69.35 $7 Million - $7.65 Million
-110,273 Reduced 15.1%
619,949 $42.7 Million
Q1 2021

May 13, 2021

BUY
$60.0 - $68.46 $1.34 Million - $1.53 Million
22,381 Added 3.16%
730,222 $47.2 Million
Q4 2020

Feb 09, 2021

SELL
$56.65 - $64.55 $6.36 Million - $7.25 Million
-112,322 Reduced 13.7%
707,841 $41.2 Million
Q3 2020

Nov 06, 2020

SELL
$62.1 - $78.08 $2.14 Million - $2.69 Million
-34,491 Reduced 4.04%
820,163 $51.8 Million
Q2 2020

Aug 12, 2020

BUY
$72.34 - $84.0 $3.65 Million - $4.23 Million
50,397 Added 6.27%
854,654 $65.8 Million
Q1 2020

May 11, 2020

SELL
$62.63 - $80.22 $8.05 Million - $10.3 Million
-128,459 Reduced 13.77%
804,257 $60.1 Million
Q4 2019

Feb 13, 2020

SELL
$61.62 - $67.78 $5.63 Million - $6.2 Million
-91,413 Reduced 8.93%
932,716 $60.6 Million
Q3 2019

Nov 12, 2019

SELL
$62.51 - $69.0 $5.52 Million - $6.1 Million
-88,370 Reduced 7.94%
1,024,129 $64.9 Million
Q2 2019

Aug 13, 2019

SELL
$61.87 - $69.38 $15.4 Million - $17.2 Million
-248,567 Reduced 18.26%
1,112,499 $75.2 Million
Q1 2019

May 14, 2019

BUY
$62.53 - $70.05 $3.52 Million - $3.94 Million
56,270 Added 4.31%
1,361,066 $88.5 Million
Q4 2018

Feb 14, 2019

SELL
$60.54 - $79.0 $1.14 Million - $1.49 Million
-18,876 Reduced 1.43%
1,304,796 $81.6 Million
Q3 2018

Nov 13, 2018

SELL
$71.28 - $78.92 $3.05 Million - $3.38 Million
-42,825 Reduced 3.13%
1,323,672 $102 Million
Q2 2018

Aug 13, 2018

SELL
$64.88 - $75.68 $9.06 Million - $10.6 Million
-139,679 Reduced 9.27%
1,366,497 $96.8 Million
Q1 2018

May 15, 2018

SELL
$72.84 - $88.8 $3.42 Million - $4.17 Million
-46,971 Reduced 3.02%
1,506,176 $114 Million
Q4 2017

Feb 14, 2018

BUY
$71.15 - $83.52 $356,532 - $418,518
5,011 Added 0.32%
1,553,147 $111 Million
Q3 2017

Nov 13, 2017

BUY
$72.11 - $85.47 $112 Million - $132 Million
1,548,136
1,548,136 $125 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $113B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Blair William & CO Portfolio

Follow Blair William & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

News

Stay updated on Blair William & CO with notifications on news.